AndroGel Side Effects: Rare but Serious Adverse Events

Why Rare Serious Adverse Events Still Demand Attention

AndroGel is one of the most prescribed testosterone replacement products in the United States, with millions of prescriptions written annually. Its tolerability profile for common side effects, things like application-site reactions, mild acne, and transient mood changes, is generally acceptable. The rare serious adverse events are a different matter.

These events occur at low absolute frequencies, but their consequences, including stroke, pulmonary embolism, and irreversible virilization in a child, are disproportionately severe relative to how rarely they appear. The FDA has updated the AndroGel label multiple times since 2000, each revision reflecting accumulating post-market safety signals. The current prescribing information consolidates those warnings into a structured risk hierarchy.

The sections below work through each major category of serious risk, anchored to primary sources, to give prescribers and informed patients the specificity needed for shared decision-making.

Secondary Exposure: The Black Box Warning

The single most prominent safety signal on the AndroGel label is secondary testosterone exposure to women, children, and adolescents through skin-to-skin contact with treated application sites.

What the FDA Label Actually Says

The FDA requires a boxed warning, the agency's strongest communication tool, specifically for this risk. FDA prescribing information for AndroGel 1.62% states that virilization has been reported in children who were secondarily exposed to testosterone gel, with documented signs including pubic hair development, clitoral or penile enlargement, advanced bone age, and aggressive behavior.

Documented Clinical Cases

Case reports published in peer-reviewed literature confirm that even brief, repeated contact with an application site can produce measurable serum testosterone elevations in a child and lead to accelerated skeletal maturation. A series reviewed by the FDA found affected children ranging from 9 months to 5 years of age. PubMed-indexed analyses of these cases confirm bone age advancement that, if sustained, can compromise adult height potential permanently.

Risk Mitigation Protocol

The label mandates that patients wash hands thoroughly after application, cover the application site with clothing once the gel dries, and wash the site before any anticipated skin-to-skin contact. Despite these instructions, accidental exposure events continue to appear in the FDA Adverse Event Reporting System (FAERS). Prescribers should document this counseling at every visit.

Cardiovascular Events: A Signal That Is Still Being Characterized

The Core Controversy

Whether testosterone therapy increases major adverse cardiovascular events (MACE) has been debated for over a decade. Early observational studies, including a 2013 JAMA Internal Medicine analysis of Veterans Affairs data (N=8,709), found a higher rate of nonfatal MI, stroke, and death in men receiving testosterone compared with those who did not, with a hazard ratio of 1.29 (95% CI, 1.04 to 1.58) for the testosterone group. That study prompted the FDA's 2015 safety communication requiring label updates for all testosterone products.

TRAVERSE Trial Data

The TRAVERSE trial (N=5,246; mean age 63.5 years; all participants had cardiovascular disease or elevated cardiovascular risk) was designed to settle the question definitively. Results published in the New England Journal of Medicine in 2023 showed that testosterone replacement was non-inferior to placebo for the primary composite MACE endpoint over a median follow-up of 33 months. The TRAVERSE publication in NEJM is now the reference standard for cardiovascular risk counseling in this population.

However, a prespecified secondary analysis found statistically higher rates of nonfatal arrhythmia, pulmonary embolism, and acute kidney injury in the testosterone arm. Atrial fibrillation occurred in 3.5% of the testosterone group versus 2.4% in the placebo group (P<0.05). That signal requires individual risk stratification before prescribing, particularly in men with existing atrial fibrillation or a history of cardiac arrhythmia.

Who Is at Greatest Cardiovascular Risk

Men with a prior MI within the past 6 months, decompensated heart failure, or a history of stroke represent populations where the risk-benefit calculation shifts materially against initiating androgen therapy. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy states: "We recommend against starting testosterone therapy in patients who have had a myocardial infarction or stroke within the last 6 months." That guideline is available through the Journal of Clinical Endocrinology and Metabolism.

Polycythemia: The Most Common Serious Lab Abnormality

Mechanism and Frequency

Testosterone directly stimulates erythropoiesis through erythropoietin-independent and erythropoietin-dependent pathways. The result is an elevation in red blood cell mass, hemoglobin, and hematocrit. Polycythemia (hematocrit above 54%) is the most frequently encountered serious laboratory abnormality in men receiving testosterone replacement.

In a systematic review of 58 randomized controlled trials (N=3,876) published in the Annals of Internal Medicine, polycythemia occurred significantly more often in testosterone-treated men, with an odds ratio of 3.67 (95% CI, 1.82 to 7.51) compared with placebo. That meta-analysis is indexed on PubMed.

Clinical Consequences

Marked polycythemia increases blood viscosity and creates a prothrombotic state. Patients with untreated polycythemia are at elevated risk for deep vein thrombosis, pulmonary embolism, and stroke. These outcomes are not merely theoretical. FAERS reports through 2023 include hundreds of cases of VTE temporally associated with testosterone product use, a dataset large enough that the FDA added an explicit VTE warning to all testosterone labels in 2014.

Monitoring and Management

The Endocrine Society recommends measuring hematocrit at baseline, at 3 to 6 months after initiating therapy, and then annually. If hematocrit rises above 54%, the guideline advises dose reduction or temporary discontinuation until levels normalize. Therapeutic phlebotomy is an option for patients who cannot tolerate dose reduction. Switching from a transdermal gel to a lower-dose formulation may attenuate the erythropoietic response in some patients.

Venous Thromboembolism: Independent of Polycythemia

A Separate Mechanism

VTE risk with testosterone may extend beyond polycythemia-driven hyperviscosity. Testosterone has been shown to alter platelet aggregation and coagulation factor activity directly. A case-control study published in BMJ (N=19,215 cases of VTE) found that testosterone use within the past 6 months was associated with an adjusted odds ratio for VTE of 1.63 (95% CI, 1.23 to 2.16), a signal that persisted after controlling for hematocrit levels. [That BMJ study](https://www.bmj.com/content/349/bmj.g4 516) is one of the largest epidemiological analyses of this association.

FDA Label Language

The current AndroGel label states under Warnings and Precautions: "There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, in patients using testosterone products. Evaluate patients who report symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT, and those who present with acute shortness of breath for pulmonary embolism." Source: FDA prescribing information.

Prostate Effects: Promotion, Not Initiation

What the Evidence Shows

Testosterone does not initiate prostate cancer from normal tissue. The saturation model, described by Morgentaler and Traish, holds that androgen receptors in prostate tissue become saturated at relatively low testosterone concentrations (roughly 250 ng/dL), meaning supraphysiologic levels add little additional stimulatory signal. A key supporting analysis is available on PubMed.

The serious concern is a different one: testosterone may promote the growth of an already-existing but undetected prostate cancer. Rapid PSA rise after initiating AndroGel can be the first clinical indicator of a pre-existing malignancy that was subclinical at baseline.

Screening Requirements

The Endocrine Society guideline recommends measuring PSA before initiating testosterone therapy and again at 3 to 6 months. A PSA increase of more than 1.4 ng/mL above baseline within any 12-month period, or a confirmed value above 4.0 ng/mL, warrants urological referral before continuing treatment. Men with a prior diagnosis of prostate cancer, or with suspected prostate cancer on digital rectal exam, should not receive AndroGel.

Hepatic Adverse Events: Mostly With Oral Androgens, but Not Zero With Gel

Peliosis Hepatis and Hepatocellular Carcinoma

Peliosis hepatis (blood-filled cysts in the liver) and hepatocellular carcinoma are documented in patients on prolonged androgen therapy. These events were first associated with 17-alpha-alkylated oral androgens, which undergo first-pass hepatic metabolism. Transdermal testosterone gel bypasses first-pass metabolism, materially reducing but not eliminating hepatic risk.

The FDA label for AndroGel nonetheless lists hepatic neoplasms and peliosis hepatis under Warnings and Precautions, based on the broader androgen class label and isolated case reports in patients with long-term transdermal use. FDA label reference.

Clinicians should obtain baseline liver function tests and monitor annually, or sooner if a patient develops unexplained right upper quadrant pain, jaundice, or hepatomegaly.

Cholestasis

Cholestatic jaundice is a recognized but rare reaction to androgens. The mechanism involves altered bile acid transport. Reports in FAERS include cholestatic hepatitis temporally linked to transdermal testosterone, though absolute incidence remains low. Patients with pre-existing hepatic impairment require careful individualized risk assessment before AndroGel is initiated.

Sleep Apnea: Exacerbation, Not New Onset

Testosterone therapy may worsen pre-existing obstructive sleep apnea. The mechanism involves testosterone's effects on upper airway muscle tone and central respiratory drive. A randomized crossover study published in the Journal of Clinical Endocrinology and Metabolism found that testosterone administration significantly worsened apnea-hypopnea index scores in men with mild pre-existing OSA. That study is indexed on PubMed.

The AndroGel label classifies sleep apnea as a Warnings and Precautions item. Before initiating therapy, prescribers should screen for OSA symptoms with validated tools such as the STOP-BANG questionnaire. Patients already using CPAP should have their titration reviewed after initiating AndroGel, as pressure requirements may change within the first few months.

Hypercalcemia: Rare but Rapid in Certain Populations

Testosterone increases bone resorption in some patients and can produce hypercalcemia, particularly in men with immobility or underlying malignancy causing bone metastases. Immobilized patients and those with metastatic bone disease are at the greatest risk.

Symptoms of hypercalcemia include confusion, excessive thirst, polyuria, and constipation. Severe hypercalcemia (serum calcium above 14 mg/dL) can produce cardiac arrhythmias and altered consciousness. The FDA label advises discontinuation of AndroGel if hypercalcemia occurs in the context of cancer metastatic to bone. FAERS cases reviewed by the FDA include reports of symptomatic hypercalcemia in this population.

Infertility and Hypothalamic-Pituitary Suppression

The Axis Shutdown Mechanism

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback on GnRH, LH, and FSH. In men of reproductive age, this suppression reduces intratesticular testosterone, which is required for spermatogenesis, often to a level insufficient to sustain sperm production. Azoospermia or severe oligospermia develops in most men on testosterone monotherapy within 3 to 6 months of initiating treatment.

This is not a pharmacological side effect in the traditional sense. It is a predictable physiological consequence of exogenous androgen administration. A systematic review published in the Journal of Urology found that testosterone use was associated with azoospermia in approximately 65% of users, with recovery of sperm production taking 6 to 18 months after discontinuation in most cases. That review is on PubMed.

Clinical Implications

Men who may wish to father children should be informed of this risk before starting AndroGel. Alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG) co-administration can preserve fertility potential while treating hypogonadal symptoms, though neither is FDA-approved specifically for this indication. This conversation should be documented in the chart.

Allergic Reactions and Contact Dermatitis

Serious hypersensitivity reactions to AndroGel are rare but documented in FAERS. Anaphylaxis and angioedema have been reported. More commonly, patients develop contact dermatitis or urticaria at the application site, occasionally severe enough to require systemic treatment. Patients with known hypersensitivity to any component of the formulation, including the hydroalcoholic gel vehicle, should not use AndroGel. Patch testing may be considered for patients with a history of contact sensitization.

A Clinical Decision Framework for Managing Serious Risk

The table below summarizes the monitoring intervals and action thresholds for the most serious AndroGel adverse events. This framework consolidates guidance from the Endocrine Society 2018 guideline, the current FDA label, and the TRAVERSE trial protocol.

| Adverse Event | Baseline Test | Recheck Interval | Action Threshold | |---|---|---|---| | Polycythemia | Hematocrit, CBC | 3-6 months, then annually | Hematocrit >54%: reduce dose or stop | | Cardiovascular | BP, lipid panel, ECG if indicated | 6 months, then annually | New arrhythmia or MACE: stop, refer cardiology | | Prostate | PSA, DRE | 3-6 months, then annually | PSA rise >1.4 ng/mL/year or >4 ng/mL: urology referral | | Hepatic | LFTs | Annually; sooner if symptomatic | Transaminases >3x ULN: discontinue | | VTE | Clinical history, Doppler if symptomatic | As clinically indicated | Confirmed DVT/PE: stop immediately | | Sleep apnea | STOP-BANG questionnaire | At initiation and if symptoms change | AHI worsening: refer sleep medicine | | Hypercalcemia | Serum calcium (if bone disease) | As clinically indicated | Calcium >12 mg/dL: hold dose, investigate | | Spermatogenesis | Semen analysis if fertility desired | Before initiation, then 3-6 months | Azoospermia: counsel, consider alternatives |

The Endocrine Society states in its 2018 guideline: "We suggest that clinicians measure hematocrit at baseline, at 3 to 6 months, and then annually. If the hematocrit exceeds 54%, stop therapy until the hematocrit decreases to a safe level, evaluate the patient for hypoxia, and reinitiate therapy at a reduced dose." Full guideline: JCEM 2018.

Post-Market Surveillance: What FAERS Adds

The FDA Adverse Event Reporting System captures spontaneous reports from clinicians, pharmacists, and patients. Because reporting is voluntary and numerator-only (no denominator of total exposures), FAERS cannot establish incidence rates or causation. It does, however, identify signals that prospective trials may be too small to detect.

For all testosterone products combined, FAERS reports through 2023 include signals for:

• Pulmonary embolism and DVT (hundreds of cases, temporally associated with initiation)
• Polycythemia leading to cerebral vascular events
• Secondary exposure virilization in children (dozens of confirmed pediatric cases)
• Anaphylaxis and severe allergic reactions
• Cholestatic jaundice

The FAERS public dashboard allows open-access querying of these signals. Clinicians can search by drug name and MedDRA preferred term to review the most current signal data. Reporting new serious adverse events directly to FAERS via MedWatch takes less than 15 minutes and strengthens the post-market evidence base for the entire prescribing community.